SNX-5422
SNX-5422 (PF-04929113), a prodrug of SNX-2112, is an orally active Hsp90 inhibitor, with a Kd of 41 nM, and also induces Her-2 degradation, with an IC50 of 37 nM.
Product Specifications
CAS Number
908115-27-5
Product Name Alternative
PF-04929113
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HSP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/PF-04929113.html
Concentration
10mM
Purity
96.52
Solubility
DMSO : 32.5 mg/mL (ultrasonic)
Smiles
FC(F)(C1=NN(C2=CC(N[C@@H]3CC[C@H](CC3)OC(CN)=O)=C(C=C2)C(N)=O)C(CC(C)(C4)C)=C1C4=O)F
Molecular Formula
C25H30F3N5O4
Molecular Weight
521.53
Precautions
H302, H315, H319, H335
References & Citations
[1]Huang KH, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem. 2009 Jul 23;52 (14) :4288-305|[2]Chandarlapaty S, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res. 2008 Jan 1;14 (1) :240-8.|[3]Kim SH, et al. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells. Endocrine. 2016 Feb;51 (2) :274-82.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUB2878-100 1x 100 µL
Ornithine Decarboxylase-1 (ODC-1) (ODC1/2878R), 0.2mg/mL
Sign In for Pricing
View Details 
